AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06517485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study NCT01614483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yellow cassava
Description: Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
Study NCT01614483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White cassava
Description: Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
Study NCT01614483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White cassava
Description: Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
Study NCT04514380 — intervention group
Intervention type: OTHER
Intervention: Carbohydrate fluid
Description: 400 mL carbohydrate fluid
Study NCT02337400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral smoking reduction program Smoke_less
Description: Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
Study NCT02337400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 15 minute counseling interview
Study NCT01988064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Description: One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
Study NCT01988064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group training
Description: Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
Study NCT01308970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 1
Description: Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
Study NCT01308970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 2
Description: Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
Study NCT04514380 — intervention group
Intervention type: OTHER
Intervention: Non-carbohydrate fluid
Description: 0 mL carbohydrate fluid
Study NCT01929811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
Study NCT01929811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study NCT01929811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study NCT01929811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study NCT01308970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 3
Description: Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
Study NCT01929811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study NCT01929811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphomide
Description: 500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study NCT03171207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lite Run Gait Trainer
Description: The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
Study NCT03171207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current Harness System
Description: There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
Study NCT01929811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphomide
Description: 500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Study NCT02436837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sessions with virtual reality
Description: sessions with virtual reality to improve the balance
Study NCT02436837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sessions with virtual reality
Description: sessions with virtual reality to improve the balance
Study NCT04254913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study NCT03412240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induced pacing of the heart
Description: Once the defibrillator leads have been inserted or, in the case of a box change, the old leads have been tested as per routine procedure, these pacing leads will be connected to an external pacing stimulator. The test involves electrically pacing your heart at different rates and we will be constantly monitoring you under close clinical supervision. During the test, your heart will be electrically stimulated to beat at a faster rate.
Study NCT02690311 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: smartphone display
Study NCT02685137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannsoporfin
Description: Intramuscular injection of stannsoporfin to treat jaundice.
Study NCT02685137 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: nothing
Study NCT03535298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Highly Effective Therapies Group
Description: Highly Effective MS Therapy group of medications
Study NCT03535298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalation Therapies Group
Description: Escalation MS Therapy group of medications
Study NCT05170880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary endodontic treatment
Description: Primary non surgical endodontic treatment will be provided to patients in treatment group.
Study NCT01032889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Study NCT01032889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study NCT01236976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therastride Treadmill System
Description: This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).
Study NCT01236976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-assisted cycling
Description: This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
Study NCT02690311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone display
Study NCT02500121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT01236976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk and upper and lower limb exercises
Description: This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.
Study NCT01236976 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Upper body strength and fitness program
Description: This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
Study NCT03308721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1177 A 1.0 mg/mL
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg.
Study NCT03308721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
Study NCT02500121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
Study NCT02949895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986012
Study NCT02949895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02949895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT03651024 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ED surgery
Description: The surgical implant for ED treatment
Study NCT05512546 — intervention group
Intervention type: DRUG
Intervention: Aspir-Low Pill
Description: patients were prescribed 75 mg/day of either aspirin
Study NCT00829192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide (CUV1647)
Description: 16 mg subcutaneous implant administered every 60 days
Study NCT00829192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous implant administered every 60 days
Study NCT01483417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single incision Laparoscopic hysterectomy
Description: SILS port
Study NCT01483417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic hysterectomy
Description: 3-4 conventional ports
Study NCT03064737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy for genetic analyze
Description: It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use.
Study NCT03111446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
Study NCT03111446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
Study NCT01035411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg batch DLE494
Study NCT01035411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg batch DLF497
Study NCT01035411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg tablet variant 1
Study NCT02512835 — intervention group
Intervention type: OTHER
Intervention: Community vital signs
Description: We will present clinicians with information about their patients' communities
Study NCT04589026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosentyx
Description: Cosentyx injection will be administered subcutaneously.
Study NCT04589026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candin
Description: Candin will be administered interadermally along with NaCl solution.
Study NCT02678390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT
Description: A 5 day consecutive MCT intake of 30 g/day.
Study NCT02396472 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Order by time and topic
Study NCT02396472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by information relevance
Study NCT02396472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by social relationship
Study NCT02396472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by help giving
Study NCT02396472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Order by self-disclosure
Study NCT04240132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence to Hand Hygiene
Description: determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
Study NCT02678390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT+ aerobic exercise
Description: A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
Study NCT03601117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation
Description: Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system.
Study NCT03601117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cingulate Cortex Accelerated Theta Burst Stimulation
Description: Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system.
Study NCT02678390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A single period of 30 minutes of aerobic exercise (70% to 80% HRR).
Study NCT02678390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control day
Description: No MCT or aerobic exercise
Study NCT00773318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT/CT guided LM/SL
Description: Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
Study NCT04194255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate
Description: iron (100 mg) supplement in form of ferrous fumarate
Study NCT01761240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-066
Description: MORAb-066 infusion.
Study NCT04194255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 15 g GOS
Description: iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
Study NCT04194255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 15 g FOS
Description: iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
Study NCT04194255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labelled iron as ferrous fumarate + 15 g acacia gum
Description: iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
Study NCT02812277 — intervention group
Intervention type: OTHER
Description: This is a Non-Interventional Study, so there are no drug or devices included.
Study NCT05386615 — intervention group
Intervention type: DEVICE
Intervention: Body System - Functional
Description: MR-Guided Focused Ultrasound
Study NCT02681237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
Study NCT02681237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Poly (ADP-ribose) polymerase (PARP) inhibitor.
Study NCT00710528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL-101
Description: CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
Study NCT03770585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided Facet joint injection
Description: Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
Study NCT00509145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod 0.6 mg capsule, oral, once daily
Study NCT00509145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, once daily, capsule
Study NCT01608932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring for frail patients with chronic diseases
Description: Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms.
Study NCT04181125 — intervention group
Intervention type: OTHER
Intervention: Biodex Balance System
Description: For the computerized evaluation of postural control, Biodex Balance System will be used.
Study NCT03770585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrsound guided Facet joint injection
Description: Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
Study NCT04181125 — intervention group
Intervention type: OTHER
Intervention: Balance Error Scoring System (BESS)
Description: For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
Study NCT01324401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut flour OIT
Description: Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
Study NCT04696614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: intervention groups provided different sequential modality of exercise
Study NCT00101452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl-l-methionine
Description: 1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
Study NCT00101452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
Study NCT00101452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules look like escitalopram capsules and SAMe capsules